Upadacitinib for the Treatment of Refractory Alopecia Areata in Pediatric Patients: A Retrospective Study

July 2026 in “ Journal of the American Academy of Dermatology ”

Wenyu Wu, Ke Tao, Ruiming Hu … J I N Y I Lin

Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer ·

We don't know much about this study yet.

Read the full study on jaad.org →

Discuss this study in the Community →

Similar research 5

Upadacitinib for the Treatment of Refractory Alopecia Areata in Pediatric Patients: A Retrospective Study Journal of the American Academy of Dermatology · 2025
Upadacitinib for the Management of Severe Alopecia Areata in Adolescent Patients: A Single-Centre Retrospective Study Clinical and Experimental Dermatology · 2024
Consistent Efficacy of Upadacitinib in Alopecia Areata Subgroups: Adult, Pediatric, Severe Disease, and JAK-Refractory Patients — A Meta-Analysis Journal of the American Academy of Dermatology · 2026
Upadacitinib for the Management of Alopecia Totalis and Subtotalis in Pediatric Patients: A Case Series Reports — Medical Cases Images and Videos · 2026
Efficacy and Safety of Upadacitinib in Adolescents and Adults with Severe Alopecia Areata: A Subgroup Analysis of the UP-AA Phase 3 Clinical Program Journal of the American Academy of Dermatology · 2026

Related Community Posts Join

6 / 1000+ results

community Drug restored full hair in 23% and over 80% of hair in 55% in 6 months

240 upvotes 3 weeks ago

An arthritis drug restored significant hair in people with alopecia areata, but it is not effective for male pattern baldness. The drug, Upadacitinib, has serious side effects and is expensive.

community 35M with alopecia areata - Treatments failing, next steps?

in Treatments 127 upvotes 2 months ago

A 35-year-old with alopecia areata has tried finasteride, topical and oral minoxidil, and dutasteride without success in stopping hair loss. The dermatologist suggests JAK inhibitors, but they are too costly, leading to uncertainty about the cause of hair loss.

community Article of all potential future cures

25 upvotes 1 year ago

Ritlecitinib and PP405 show promise for hair regrowth. Diagnosing the cause of hair loss is crucial before treatment.

community Kintor Pharma Announces Completion of First Patient Enrollment in KX-826 Long-term Safety Phase III Trial for Treatment of AGA

13 upvotes 3 years ago

Kintor Pharma has finished enrolling the first patient in a Phase III trial for KX-826, a treatment for androgenetic alopecia (AGA). One user has set a reminder to check back on the topic in a year.

community Alopecia Areata Question

2 upvotes 5 years ago

A user with alopecia totalis, borderline universalis, seeks advice on getting into a Xeljanz trial or appealing insurance for coverage. They experienced significant hair regrowth but are now seeing hair loss again and want to try Xeljanz.

community What are the odds baricitinib will get a topical otc version for androgenic alopecia?

3 years ago

Baricitinib, approved for alopecia areata, might be considered for treating receding hairlines. The discussion is about the possibility of an over-the-counter topical version for androgenic alopecia.